Baricitinib Effectiveness in JAKi-Naïve and Tofacitinib-Exposed Patients: A Prospective Study in Alopecia Areata

    January 2025 in “ Dermatologic Therapy ”
    Daniel Muñoz‐Barba, Carmen García‐Moronta, Sofía Haselgruber … Salvador Arias‐Santiago
    Studysummary This study found that baricitinib significantly reduced alopecia severity in JAK inhibitor-naïve patients compared to those previously treated with tofacitinib, indicating that switching JAK inhibitors can be safe and may be beneficial for selected patients with partial prior responses.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on onlinelibrary.wiley.com →
    Discuss this study in the Community →

    Research cited in this study 19

    1. Real-World Effectiveness and Safety of Janus Kinase Inhibitors in Alopecia Areata: A Retrospective Cohort Study of 72 Patients Acta Dermato Venereologica · 2025
    2. Switching JAK Inhibitors: Evaluating Baricitinib’s Effectiveness in Alopecia Areata After Tofacitinib Failure Archives of Dermatological Research · 2025
    3. Predictive Factors for Treatment Responses to Baricitinib in Severe Alopecia Areata: A Retrospective, Multivariate Analysis of 70 Cases from a Single Center The Journal of Dermatology · 2025
    4. Novel Investigational Drugs for Alopecia Areata and Future Perspectives Expert opinion on investigational drugs · 2024
    5. Effectiveness and Predictive Factors of Response to Tofacitinib Therapy in 125 Patients with Alopecia Areata: A Single-Centre Real-World Retrospective Study Acta dermato-venereologica · 2023
    6. Exploring the Efficacy of Baricitinib in Treating Alopecia Areata After Failed Janus Kinase Inhibitor Therapy JAAD Case Reports · 2023
    7. Real-Life Effectiveness and Tolerance of Baricitinib for the Treatment of Severe Alopecia Areata with 1-Year Follow-Up Data Dermatology and Therapy · 2023
    8. Alopecia Areata: Current Treatments and New Directions American Journal of Clinical Dermatology · 2023
    9. Janus Kinase Inhibitors for Alopecia Areata Journal of the American Academy of Dermatology · 2023
    10. Efficacy and Safety of Different JAK Inhibitors in the Treatment of Alopecia Areata: A Network Meta-Analysis Frontiers in immunology · 2023
    11. Efficacy and Safety of Ritlecitinib in Adults and Adolescents With Alopecia Areata: A Randomised, Double-Blind, Multicentre, Phase 2b–3 Trial The Lancet · 2023
    12. Switching Between Tofacitinib and Baricitinib in Alopecia Areata: A Review of Clinical Response Journal of the American Academy of Dermatology · 2023
    13. Alopecia Areata: Burden of Disease, Approach to Treatment, and Current Unmet Needs Clinical, Cosmetic and Investigational Dermatology · 2023
    14. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata Over 52 Weeks in Phase III Trials American Journal of Clinical Dermatology · 2023
    15. Ideal JAK Inhibitor for Alopecia Areata: Baricitinib, Tofacitinib, Ritlecitinib, or Ifidancitinib - Revisiting the Immunomechanisms of the JAK Pathway Indian Dermatology Online Journal · 2023
    16. JAK Inhibitors for Alopecia Areata: A Systematic Review and Meta-Analysis JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology · 2019
    17. SALT II: A New Take on the Severity of Alopecia Tool for Determining Percentage Scalp Hair Loss Journal of The American Academy of Dermatology · 2016
    18. Translational Positioning of Janus Kinase (JAK) Inhibitors in Alopecia Areata EBioMedicine · 2015
    19. Inhibiting Janus Kinases to Treat Alopecia Areata Nature medicine · 2014